Research programme: Rho GTP-binding protein inhibitors - ExonHit Therapeutics
Alternative Names: EHT 0101; EHT 0206; EHT 101; EHT 1864; EHT 206Latest Information Update: 04 Nov 2017
At a glance
- Originator ExonHit Therapeutics
- Developer Eurobio Scientific
- Class Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors; GTP phosphohydrolase inhibitors; Ras signal transduction pathway inhibitors; Rho GTP-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease; Cancer; Chronic myeloid leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chronic-myeloid-leukaemia in France